BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19451445)

  • 1. Adjuvant hormonal therapy use among insured, low-income women with breast cancer.
    Kimmick G; Anderson R; Camacho F; Bhosle M; Hwang W; Balkrishnan R
    J Clin Oncol; 2009 Jul; 27(21):3445-51. PubMed ID: 19451445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.
    Neugut AI; Subar M; Wilde ET; Stratton S; Brouse CH; Hillyer GC; Grann VR; Hershman DL
    J Clin Oncol; 2011 Jun; 29(18):2534-42. PubMed ID: 21606426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas.
    Kim J; Kim MS; Rajan SS; Du XL; Franzini L; Kim TG; Giordano SH; Morgan RO
    Curr Oncol; 2023 Mar; 30(4):3800-3816. PubMed ID: 37185401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.
    Weaver KE; Camacho F; Hwang W; Anderson R; Kimmick G
    Am J Clin Oncol; 2013 Apr; 36(2):181-7. PubMed ID: 22314001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
    Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
    J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.
    Felder TM; Do DP; Lu ZK; Lal LS; Heiney SP; Bennett CL
    Breast Cancer Res Treat; 2016 May; 157(1):193-200. PubMed ID: 27120468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    Farias AJ; Wu WH; Du XL
    BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.
    Kim J; Rajan SS; Du XL; Franzini L; Giordano SH; Morgan RO
    Breast Cancer Res Treat; 2018 Jun; 169(3):573-586. PubMed ID: 29423900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
    Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
    JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
    Livaudais JC; Hershman DL; Habel L; Kushi L; Gomez SL; Li CI; Neugut AI; Fehrenbacher L; Thompson B; Coronado GD
    Breast Cancer Res Treat; 2012 Jan; 131(2):607-17. PubMed ID: 21922245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.
    Zheng D; Thomas J
    Breast Cancer Res Treat; 2023 Aug; 201(1):89-104. PubMed ID: 37326766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
    Neugut AI; Zhong X; Wright JD; Accordino M; Yang J; Hershman DL
    JAMA Oncol; 2016 Oct; 2(10):1326-1332. PubMed ID: 27281650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer.
    Zhao H; Lei X; Niu J; Zhang N; Duan Z; Chavez-MacGregor M; Giordano SH
    JCO Oncol Pract; 2021 Jun; 17(6):e794-e808. PubMed ID: 33596096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
    Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income.
    Ursem CJ; Bosworth HB; Shelby RA; Hwang W; Anderson RT; Kimmick GG
    J Womens Health (Larchmt); 2015 May; 24(5):403-8. PubMed ID: 25884292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
    Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
    Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
    Hershman DL; Shao T; Kushi LH; Buono D; Tsai WY; Fehrenbacher L; Kwan M; Gomez SL; Neugut AI
    Breast Cancer Res Treat; 2011 Apr; 126(2):529-37. PubMed ID: 20803066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.
    Neuner JM; Fergestrom NM; Laud PW; Nattinger AB; Beyer KMM; Flynn KE; Pezzin LE
    Cancer; 2019 Nov; 125(22):3960-3965. PubMed ID: 31373689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
    Murphy CC; Tiro JA; Jean GW; Balasubramian BA; Alvarez CA
    J Womens Health (Larchmt); 2017 Jun; 26(6):655-661. PubMed ID: 28296574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.